List view / Grid view
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
CUVITRU is a treatment for patients with primary immunodeficiency (PI), a group of more than 300 genetic disorders in which part of the body's immune system is missing or functions improperly...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Mino-Lok is being developed as an adjunctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI)...
20 September 2016 | By Niamh Louise Marriott, Digital Content Producer
APX001 is a small molecule drug candidate that targets and inhibits the conserved fungal enzyme Gwt1, compromising fungal growth of major fungal pathogens...
19 September 2016 | By ABITEC Corporation
ABITEC Corporation continues to add new innovations and dosage form applications to their already expansive product portfolio...
16 September 2016 | By PCI Pharma Services
Leading pharmaceutical provider PCI Pharma Services will bring its expertize to the stage at CPHI Worldwide (Barcelona, October 4-6 2016) with two Speakers Corner slots at the ICSE Exhibitor Showcase...
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Sirukumab is a human monoclonal IgG1 kappa antibody that targets the cytokine IL-6, a protein believed to play a role in autoimmune rheumatoid arthritis...
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
EB-101 is the company's lead gene therapy program for patients suffering with recessive dystrophic epidermolysis bullosa (RDEB), a severe form of...
16 September 2016 | By Niamh Louise Marriott,
The European Commission has approved Ibsen’s cabometyx (cabozantinib) 20, 40, 60 mg tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy. Cabometyx (cabozantinib) demonstrated significant clinical benefits across all three efficacy endpoints (OS, PFS, ORR) in a phase 3…
16 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Gilenya impacts four key measures of disease activity: relapses, MRI lesions, brain shrinkage (brain volume loss) and disability progression...
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Senscis is specifically evaluating nintedanib to understand the disease process and potential benefit of the compound to treat SSc-ILD...
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The Australian Therapeutic Goods Administration (TGA) has granted orphan drug designation to Santhera Pharmaceutical’s idebenone (raxone) for the treatment of Duchenne muscular dystrophy (DMD). The product has already received ODD from European, Swiss and US authorities...
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The effects of lorediplon (5 and 10 mg) are being compared to both placebo and zolpidem. The aim of the study is to evaluate the appropriate effective dose of lorediplon, to further characterise its efficacy on sleep maintenance/sleep quality and to evaluate any next day hangover effects in adult patients…
13 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The discoveries include DNA changes in three rare genes that have much larger effects on blood pressure in the population than previously seen, providing new insights into the physiology of hypertension and suggesting new targets for treatment...
8 September 2016 | By Coulter Partners
Coulter Partners was delighted to partner with Erytech Pharma to secure the appointment of Allene M. Diaz to its Board of Directors as a nonvoting member (censeur)...
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The coil is the most effective form of emergency contraception for up to 5 days after unprotected sex or within 5 days of expected ovulation...
